Ironjustic
Thu, May-17-07, 17:16
<<snip>> Hydroyxurea provides a novel and useful therapeutic
approach to reduce hyperviscosity from secondary
erythrocytosis in patients with CCHD <<snip>>
Am J Hematol. 2007 May 15; [Epub ahead of print]Hydroxyurea
therapy for management of secondary erythrocytosis in cyanotic
congenital heart disease.Reiss UM, Bensimhon P, Zimmerman SA,
Ware RE. Department of Hematology, St. Jude Children's
Research Hospital, Memphis, Tennessee.
Secondary erythrocytosis in cyanotic congenital heart disease
(CCHD) causes substantial morbidity because of complications
of hyperviscosity, including stroke and chronic end organ
damage. Phlebotomy provides temporary improvement but leads to
iron deficiency and can actually increase blood viscosity. We
describe the successful use of hydroxyurea (hydroxycarbamide)
in four patients with uncorrected CCHD and symptomatic
secondary erythrocytosis. In all patients, hydroxyurea
improved symptoms of hyperviscosity. Substantial decreases in
the red blood cell (RBC) count were observed, along with
increases in the mean corpuscular volume (MCV) and mean
corpuscular hemoglobin (MCH), leading to only modest declines
in the circulating hemoglobin concentration. Two patients
experienced transient mild myelosuppression, which promptly
resolved with dose reduction of hydroxyurea. Hydroyxurea
provides a novel and useful therapeutic approach to reduce
hyperviscosity from secondary erythrocytosis in patients with
CCHD, while preserving oxygen carrying capacity and avoiding
iron depletion by phlebotomy. Am. J. Hematol., 2007. (c) 2007
Wiley-Liss, Inc.
PMID: 17506064 [PubMed - as supplied by publisher]
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk
approach to reduce hyperviscosity from secondary
erythrocytosis in patients with CCHD <<snip>>
Am J Hematol. 2007 May 15; [Epub ahead of print]Hydroxyurea
therapy for management of secondary erythrocytosis in cyanotic
congenital heart disease.Reiss UM, Bensimhon P, Zimmerman SA,
Ware RE. Department of Hematology, St. Jude Children's
Research Hospital, Memphis, Tennessee.
Secondary erythrocytosis in cyanotic congenital heart disease
(CCHD) causes substantial morbidity because of complications
of hyperviscosity, including stroke and chronic end organ
damage. Phlebotomy provides temporary improvement but leads to
iron deficiency and can actually increase blood viscosity. We
describe the successful use of hydroxyurea (hydroxycarbamide)
in four patients with uncorrected CCHD and symptomatic
secondary erythrocytosis. In all patients, hydroxyurea
improved symptoms of hyperviscosity. Substantial decreases in
the red blood cell (RBC) count were observed, along with
increases in the mean corpuscular volume (MCV) and mean
corpuscular hemoglobin (MCH), leading to only modest declines
in the circulating hemoglobin concentration. Two patients
experienced transient mild myelosuppression, which promptly
resolved with dose reduction of hydroxyurea. Hydroyxurea
provides a novel and useful therapeutic approach to reduce
hyperviscosity from secondary erythrocytosis in patients with
CCHD, while preserving oxygen carrying capacity and avoiding
iron depletion by phlebotomy. Am. J. Hematol., 2007. (c) 2007
Wiley-Liss, Inc.
PMID: 17506064 [PubMed - as supplied by publisher]
Who loves ya. Tom
Jesus Was A Vegetarian! http://jesuswasavegetarian.7h.com
Man Is A Herbivore! http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING http://tinyurl.com/zk9fk